SecBot SecBot
8-K ·Filed Jun 12, 2026

XOMA

XOMA Royalty Corp
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001193125-26-269734
8-K context-dependent: Items 7.01, 8.01
Actionable Insight • Neutral

For common stock holders, the merger timeline solidification and preferred redemption remove overhang and simplify the capital structure ahead of the acquisition. Monitor the stockholder vote and regulatory approvals for the Ligand deal. For preferred holders, redeemable securities should be sold before the July 14 redemption date or held to receive $25-plus-dividend cash-out; post-redemption the tickers (XOMAP, XOMAO) will be delisted.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$41.95
T+0 close · Jun 12, 2026 · via day close
Latest settled
−4.24%
T+20 · $40.17
Vs SPY
−3.49%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 15 $41.95entry
  2. T+1 · 5mo ago −0.41%α +0.19% · $41.78
  3. T+5 · 5mo ago +0.12%α +1.50% · $42.00
  4. T+20 · 4mo ago −4.24%α −3.49% · $40.17
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

XOMA Royalty Corp announced that the previously announced acquisition by Ligand Pharmaceuticals is expected to close on or about July 14, 2026, and simultaneously called for full redemption of its two outstanding perpetual preferred stock series (XOMAP and XOMAO) at $25 per share/share-equivalent plus accrued dividends, effective the same date. The redemption is a direct consequence of the pending merger, and a CVR record date for common stockholders was also set for July 13, 2026.

Key Facts

  • Merger with Ligand expected to close on or about July 14, 2026
  • All 984,000 shares of 8.625% Series A Preferred (XOMAP) and 1,760,500 depositary shares of 8.375% Series B Preferred (XOMAO) to be redeemed at $25.00 each on July 14, 2026
  • Final quarterly dividends declared: $0.53906 per Series A share, $0.52344 per Series B depositary share, payable July 15 to record holders of July 2
  • CVR record date for common stockholders set at 5:00 p.m. ET on July 13, 2026
  • Preferred stock to be delisted from Nasdaq upon completion of redemption
  • Redemption is conditioned on completion of the Ligand acquisition

Financial Impact

Total redemption cost of approximately $68.6 million (Series A: ~$24.6M, Series B: ~$44.0M) plus accrued dividends; represents ~13% of XOMA's $524M market cap

dilutiondebtdividend

Risk Factors

  • Merger closing conditions (stockholder approval, regulatory clearances) may not be satisfied or waived by July 14
  • CVR value is contingent on the Janssen litigation outcome and may be zero
  • Preferred redemption reduces cash on hand ahead of merger close

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-269734
Document: d143305dex991.htm0001193125-26-269734
Document: 0001193125-26-269734-index-headers.html0001193125-26-269734
Document: 0001193125-26-269734-index.html0001193125-26-269734
Document: 0001193125-26-269734.txt0001193125-26-269734

Track record

8 reports on XOMA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +52.83% at T+60 after the Mar 18, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Jul 27, 202616w ago 15-12G Bearish 7/10 No price data
  2. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $40.17 to $40.17 · 0.00% +0.47% vs SPY
  3. Jun 12, 202622w ago DEFA14A Bullish 8/10 Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
  4. Jun 12, 202622w ago 8-K Neutral 4/10 Viewing Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
  5. Mar 18, 202634w ago Press Release Neutral 3/10 Entry $28.76 to $30.53 ▲ +6.15% +8.37% vs SPY
  6. Mar 18, 202634w ago 8-K Neutral 4/10 Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
  7. Mar 18, 202634w ago Press Release Bullish 8/10 Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
  8. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $26.86 to $28.76 ▲ +7.07% +8.05% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026